# Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

> **NCT03886649** · PHASE1 · TERMINATED · sponsor: **Swiss Cancer Institute** · enrollment: 7 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Copanlisib
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03886649
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-04
- **Primary completion:** 2021-05-10
- **Final completion:** 2022-03-08
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Insufficient Funding
- **Last updated:** 2022-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03886649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03886649, "Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03886649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*